ZL-1310 Clinical Trials

4 actively recruiting trials across 4 locations

▲ +1 trial since May 2026

Pipeline

Phase 1: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

Zai Lab (Shanghai) Co., Ltd.3
Amgen1

Indications

Cancer4
Lung Cancer3
Small Cell Lung Cancer2
SCLC1
Solid Tumors1

Duarte, California1 trial

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Zai Lab Site 2005

Phase 1

San Francisco, California1 trial

A Study of ZL-1310 in Participants With Selected Solid Tumors

Zai Lab Site 2001

Phase 1/2

Aurora, Colorado1 trial

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

Zai Lab Site 02037

Phase 3

New York, New York1 trial

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

New York University Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.